Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, November 18, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Anupam Rama Maintained (VERA) at Buy with Increased Target to $38 on, Nov 18th, 2022
Anupam Rama of JP Morgan, Maintained "Vera Therapeutics, Inc." (VERA) at Buy with Increased Target from $35 to $38 on, Nov 18th, 2022.
Anupam has made no other calls on VERA in the last 4 months.
There is 1 other peer that has a rating on VERA. Out of the 1 peers that are also analyzing VERA, 0 agree with Anupam's Rating of Hold.
This is the rating of the analyst that currently disagrees with Anupam
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $36 on, Monday, August 22nd, 2022
